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Familial Mediterranean fever (FMF), which is the prototype of the hereditary 
periodic fever syndromes, is common in the countries around the Mediterranean 
Sea. Considering its geographical position in the northwest of Iran, with its 
population of Turkish origin and its vicinity to the Mediterranean Sea, the 
incidence of FMF should be high in Ardabil. The goal of this study was to 
introduce FMF as a disease with significant outbreak in this area.
Based on the Tel-Hashomer criteria, patients suffering from FMF were collected 
from private clinics together with the medical records of adult and pediatric 
rheumatology clinics. Of 112 total patients determined, 74 were studied. All 
of the patients were interviewed and completed a questionnaire.
Familial Mediterranean fever was common among children under 18 years 
(76%), and it was more common in males than females (M/F 1.17). Abdominal 
pain was the most common complaint (74%) and abdominal pain and fever 
(95% and 84%, respectively) were the main clinical symptoms. The average 
duration of pain was 12-72 hours and the average recovery (attack-free period) 
was from one week to one month (63.5%). The majority of the patients 
had hospital admission for diagnostic work-up (85%) and some (32%) had 
undergone surgical operation erroneously; 92% of the patients had taken 
medications with incorrect diagnosis; and 20% had positive familial history 
of FMF. Fifty percent of the patients’ parents were first-degree relatives and 
in 59.5% delay in diagnosis was more than three years.
It seems that FMF is more common in the Northwest of Iran than previously 
thought, although physicians are not familiar with it.
The common age for manifestation of this disease is under 18 years and its 
presentation after the age of 40 years is very rare.
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Familial Mediterranean fever (FMF) is the most 
common form of the hereditary periodic fever 
syndromes, which has autosomal recessive 
pattern and presents with self-limited periodic 
fever and serositis in its classic form1,2. Jewish, 
Armenian, Arab and Turkish people, i.e. people 
of Mediterranean origin, are affected by the 
disease3. MEFV is the responsible gene in 
this disease and it is located on the short arm 
of chromosome 16 near the gene responsible 
for polycystic kidney disease2,4. The mutation 
of this gene leads to defect in synthesis of a 
protein known as pyrin-marenostrin5,6. This 
protein, along with other proteins involved in 
cell death, has a role in control and regression 
of the inflammatory cycle. Its deficiency also 
leads to continuous inflammation, inflammatory 
explosion and finally to febrile serositis2,7,8.
More than 50 mutations in the gene on 
chromosome 16 have been recorded7, but there 
are five main mutations in people affected by 
FMF, and 91% of the patients have one of 
these five mutations, which include: M694V 
(common version), M680I, M694I, E148Q and 
V720S6. These various mutations explain the 
different phenotypes in FMF patients9. M694V 
mutation is interrelated with severe clinical 
presentation, more incidences in arthritis and 
its progression toward amyloidosis10,11.
Cytokines like interleukin (IL)-2, IL-6, IL-8 
and IL-10 have roles in the pathogenesis of 
the disease12,13.
In the attack-free period, the existence of 
protracted subacute clinical inflammation has 
been described14. Abdominal pain because of 
sterile serositis is the most common clinical 
symptom in FMF5,15. The pain may be so 
severe that it may mimic acute abdomen. Chest 
pain has been reported in more than 50% of 
the patients5. The classic arthritis in FMF is 
a self-limited monoarthritis; half of patients 
have arthralgia, but destructive arthritis and 
sacroiliitis are very rare16,17. Myalgia has 
been reported in FMF in less than 20% of 
patients, typically lasting for less than two 
days5. The most common myalgia that has 
been described in FMF is activity-dependent 
myalgia (18%)18.
Skin rash in FMF is an erysipelas-like 
erythema19. Aseptic meningitis, headache, 
pericarditis and hematuria and orchitis are 
other symptoms of this disease4-6,9,20.
The only truly accepted diagnostic method 
is the analysis of the MEFV gene5,21, though 
“reverse hybridization” and “nuclei and 
nucleolar organizing regions” are other newly 
introduced means of diagnosis22,23.
Familial Mediterranean fever association with 
some diseases such as juvenile idiopathic 
arthritis (JIA), Addison, inflammatory bowel 
disease, chronic myelogenous leukemia (CML), 
Helicobacter pylori infection and Behçet’s disease 
has been described5,24-30.
Colchicine is the only effective treatment; this 
medication is effective in 95% of patients but 
5% show resistance5,31. Today, intravenous 
colchicine32, interferon alpha administration33, 
and tumor necrosis factor (TNF) receptor 
blockers34 have been used successfully in 
patients who were colchicine-nonresponsive.
Material and Methods
This is a descriptive study conducted in the 
northwest of Iran (Ardabil). We studied the 
medical records of these patients from adult 
and pediatric (under 18 years) rheumatology 
as well as some private clinics. In total, we 
obtained a list of 112 affected or suspected 
patients. Fifteen patients did not agree to 
participate, 20 had no address or phone number 
and 3 did not enter the study because of other 
diagnoses. Consequently, 74 patients were 
enrolled in the study.
We used Tel-Hashomer criteria for diagnosis 
of FMF. Tel-Hashomer criteria, with major 
and minor criteria, have been described as 
a diagnostic criterion of FMF. It is also very 
valuable in the areas where FMF is common. 
Major criteria include 1- Recurrent fever together 
with serositis, 2- AA amyloidosis without 
any other susceptible agent, and 3- Good 
response to continual treatment with colchicine. 
Minor criteria also include 1- recurrent fever, 
2- Erysipelas-like erythema, and 3- Positive 
familial background. Two major criteria or two 
minor criteria along with one major criterion 
indicate definite diagnosis of disease. However, 
one major criterion with one minor indicates 
probable diagnosis of disease4.
All had definitive Tel-Hashomer criteria, 
and they all completed a questionnaire. We 
abstracted age, gender, age of onset, periodicity, 
all symptoms and signs, parental consanguinity, 
family history, period of treatment, dosage of 
colchicine, clinical response, and side effects. 
According to subjective criteria, pain intensity 
was evaluated in a range of 1-10, with a score 
of 1-4 considered as mild pain, 5-7 as moderate 
pain and 8-10 as severe pain.
The collected data were analyzed with SPSS 
software.
Results
Of the 74 patients, 40 (54%) were male and 
34 (46%) female. Eighty-four percent of the 
patients were in the pediatric group, among 
whom those aged 1-10 years were the most 
affected. The onset of symptoms was often in 
the childhood period (Table I).
Incidence of disease in the pediatric group 
was most common between 2-4 years of age 
and in adults between 25-30 years. Abdominal 
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Table I. Age at Onset of Clinical Presentation
Age Number of patients Percent
Infant  8 10.8%
 1-10 yrs 36 48.7%
10-20 yrs 18 24.3%
20-40 yrs 10 13.5%
40-50 yrs 01  1.3%
50-55 yrs  1  1.3%
Total 74 100%
Table II. Main Complaints of Patients
Main complaint Number of patients Percent
Abdominal pain 55 74.3%
Chest pain  5  6.8%
Irritability  4  5.4%
Fever  4  5.4%
Respiratory discomfort  1  1.4%
Constipation  1  1.4%
Arthritis  1  1.4%
Arthralgia  1  1.4%
Headache  1  1.4%
Chill  1  1.4%
Total 74 100%
pain (74%) and chest pain (6.8%) were the 
main complaints among the patients. The other 
clinical complaints are listed in Table II.
Most of the patients (78%) had severe pain, 
17.5% had moderate, and the remainder (4.5%) 
suffered from mild pain.
The average duration of pain was 12-72 hours 
in 76% of the patients. In 13.5%, it was more 
than 72 hours and in the remainder less than 
12 hours. The average pain-free period was 
one week to one month (63.5%).
Systemic symptoms such as fever, chill, malaise 
and weakness were reported in 99% of the 
patients and symptoms of digestive tract were 
observed in 97%. Involvement of the other 
organs is shown in Figure 1.
The most common symptoms were abdominal 
pain (95%) and fever (84%) and the remainder 
are shown in Table III.
Three patients had goiter. One of them was 
euthyroid, another hypothyroid and the third 
hyperthyroid. Eye symptoms were blurred 
vision, conjunctivitis, erythema, and edema 
around the eye. Chest pain was noted in 24%, 
constipation in 42% and paresthesia in 22%.
Fig. 1. Prevalence of organ involvement in patients.
All of the patients were of Turkish origin. Fifty-
four percent of the patients had a history of 
hospital admission, 32% had undergone surgical 
operations with acute abdomen and laparotomy 
and 91% had taken wrong medications.
Table III. Prevalence of Different Clinical 
Symptoms in Patients
Clinical symptoms Percent
Number of
patients
Fever 83.8 62
Anorexia 81.1 60
Chill 60.8 45
Weakness 59.9 44
Anathema  6.8  5
Exanthema 12.2  9
Headache 40.5 30
Blurred vision  8.1  6
Conjunctivitis 36.5 27
Palpitation 35.1 26
Respiratory distress 43.2 32
Chest pain 24.3 18
Nausea 71.6 53
Vomiting 63.5 47
Abdominal pain 94.6 70
Diarrhea 18.9 14
Constipation 41.9 31
Change in urine color 39.2 29
Dysuria 28.4 21
Myalgia   23 17
Arthralgia 37.8 28
Arthritis   23 17
Vertigo 28.4 21
Paresthesia 21.6 16
Tremor  6.8  5
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Antibiotics (38%), non-steroidal anti-inflammatory 
drugs (NSAIDS) (35%) and antipyretics (30%) 
were the most commonly used drugs. Emergency 
surgical operation (31%) and infectious diseases 
such as parasitic infection (20%) were common 
mis-diagnoses.
Twenty percent had positive family history 
of FMF and 7% of their relatives had similar 
symptoms, but they had no medical evaluation. 
Parental consanguinity was present in 50% 
of the patients. The patients’ response to 
colchicine was good in 78% (symptom-free), 
moderate in 5% (50% response) and poor in 
4% (no response); the remainder of the patients 
were newly diagnosed and had not taken the 
drug for more than six months. Diarrhea was 
the common side effect of colchicine (24%).
Amyloidosis was present in 2.7% of the patients 
and resulted in death in two patients. There 
was no statistically significant relationship 
between sex and severity of disease (p=0.6). 
A statistically significant relationship was 
determined between arthritis and the pediatric 
age group (p=0.008). The relationships 
between arthralgia and chest pain in the 
pediatric group and fever in the adult group 
were also statistically significant (p=0.009, 
p=0.024, p=0.007, respectively).
Discussion
The first group of pediatric FMF cases 
(13 patients) from the northwest of Iran was 
reported by Salehzadeh et al.35 at the Tehran 
International Pediatric Congress in 1994, and 
the present study is the second global report 
from this area. Geographical location, population 
of Turkish origin, proximity to Armenia 
and immigration are the main contributing 
reasons for its prevalence. Familial marriage 
(consanguinity) is another possible factor.
The high frequency of emergency operation, 
erroneously performed more than once in some 
patients, and various inappropriate medications 
given due to incorrect diagnosis indicate that 
it is still a largely unknown disease in Iran.
In this study, 84% of the patients were under 
the age of 20. Pain intensity is different, as 
reported in similar studies5,6. In this study, 
most of the patients complained of severe 
pain. The duration of each attack is usually 
12-72 hours5,6, which was also comparable 
with results in our patients. The pain-free 
interval also varies in the different studies11. 
The average attack-free interval of disease in 
our study was one week to one month, and 
then 1-2 months.
Fever is seen in all patients but it may be 
ignored5. In our study, fever was observed 
in 84% of the patients. Fever and abdominal 
pain are the common clinical symptoms in 
children and in adults21; 94.6% of our patients 
had abdominal pain. In our group, 4% had 
thyroid dysfunction and variation in thyroid 
size. This finding may be related to the onset 
of systemic amyloidosis coexistent with other 
auto-inflammatory disorders.
Myalgia has been reported in 20% of the 
patients5, and 23% of our patients had activity-
related myalgia. Joint involvements in the 
form of arthritis or arthralgia are seen in 50% 
of the patients5. In our study, the rate was 
higher, and in 1% of the patients, arthritis had 
developed as a destructive arthritis. Regarding 
the high incidence of joint involvement and its 
relation with the M694V mutation, this kind 
of mutation may be common in this region.
In the adult group, 2.7% of the patients were 
using opium as a pain-relieving agent. In 4% 
of the patients, response to colchicine was very 
poor although in some it could be related to 
inadequate dosage of drug, or to its interrupted 
use. Diarrhea was the common side effect 
of colchicine.
There is a relation between amyloidosis and 
sex, with a male predominance11. In our study, 
both patients with amyloidosis were male.
This study shows a large number of FMF 
patients from the northwest of Iran and indicates 
the high frequency of FMF in this region.
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